Investigation of Methylation Changes of ctDNA From Peripheral Blood in Patients With Lung Cancer by Digital PCR
Project no. 20984 · Status: Kapanmış (Yayın bekleniyor) · 2019
Summary
Objective: Lung cancer, leading to the most common death in both sexes, is the most common malignancy worldwide. The most common cause of lung cancer is cigarette smoke. In the early diagnosis of lung cancer in smokers, screening with low-dose computed tomography has been proposed. Due to the disadvantages of this screening such as misdiagnosis, cost and time loss; non-invasive and sensitive biomarkers were needed for early diagnosis of lung cancer. In this study, it was aimed to evaluate the methylation changes detected by droplet digital PCR (ddPCR) measurement of 6 genes (RASSF1A, p16, SHOX2, RARß2, APC, DAPK1) known to be associated with lung cancer determined by the literature scan in cfDNA (cell-free DNA) obtained from the plasma of patients diagnosed with advanced-non-small cell lung cancer. Materials and Methods: cfDNA was obtained from peripheral blood plasma samples of 10 patients and 10 controls included in the study. With the literature review, 6 target gene promoter regions were determined. After bisulfite transformation of target gene regions in cfDNA, methylation analysis was performed with ddPCR. The results were analyzed statistically. Results: In the study, a significant difference was found between the patient and control groups in the methylation levels of the DAPK1 gene in the promoter region (p <0,05). In 8 of 10 patients included in the study, significant methylation height in the DAPK1 gene was detected. Hypermethylation in the DAPK1 gene has been found to be compatible with the literature. Conclusion: Our study has been one of the leading studies in our country that perform methylation analysis from cfDNA in lung cancer with ddPCR. It contributed to the literature with the detection of hypermethylation in the DAPK1 gene in non-small cell lung cancer. Our study is a preliminary study for further studies in this field with more patients.